REG - RTW Biotech Opp. - Corxel completes $287 million Series D-1 financing

RTW Biotech OpportunitiesAnnouncement

23/01/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260123:nRSW0399Qa&default-theme=true

RNS Number : 0399Q  RTW Biotech Opportunities Ltd  23 January 2026

LEI: 549300Q7EXQQH6KF7Z84

23 January 2026

RTW Biotech Opportunities Ltd

Corxel completes $287 million Series D-1 financing

·      RTW Bio's largest private investment raises up to $287 million
from a syndicate of global investors

·      Proceeds to support the advancement of its lead programme across
ongoing clinical trials

·      The Company converted its convertible notes as part of the
financing round

RTW Biotech Opportunities Ltd (the "Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to the note the announcement by private portfolio company Corxel
Pharmaceuticals Limited ("Corxel") of the completion of a $287 million Series
D-1 financing.

Corxel is a clinical-stage biopharmaceutical company dedicated to developing
innovative therapies for patients with cardiometabolic conditions around the
world. Its lead product candidate, CX11, is an oral GLP-1 receptor agonist for
obese and overweight patients currently in a Phase 2 trial in the United
States.

 

As of 31 December, Corxel represented 6.2% of the Company's NAV. It is the
Company's largest private position and represents a quarter of the Company's
overall private investment exposure. RTW Bio converted its convertible notes
into Series D-1 shares as part of the Series D1 financing, which saw
participation from a syndicate of global healthcare-focused investors,
including RTW Investments, SR One Capital Management, TCG Crossover, RA
Capital Management, HBM Healthcare Investments and SymBiosis. RTW Bio's
pro-forma holding of Corxel is valued at $53.9 million.

 

Proceeds are expected to support the advancement of CX11 in its Phase 2 trial
in the United States, its planned global Phase 2 trial to treat Type 2
Diabetes Mellitus, and initial preparations for Phase 3 trials as well as
other cardiometabolic programs.

 

Rod Wong, CIO of RTW Investments, said, "We believe CORXEL's clinical
progress, disciplined execution, and seasoned leadership team position the
company for important near-term catalysts and sustained long-term value
creation. We are excited to support their journey toward becoming a leading
biotech in the field of cardiometabolic disorders."

 

Corxel's announcement can be found here
(https://www.corxelbio.com/en/press-releases/corxel-announces-287-million-series-d1-financing-to-further-advance-its-cardiometabolic-pipeline-including-oral-small-molecule-glp-1-receptor-agonist/)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Nathan Brown

 Duncan Monteith

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/) for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUBRGDBBXDDGLD



            Copyright 2019 Regulatory News Service, all rights reserved